Ya.A. Azarova
Research Subjects
Research Interests
Ya.A. Azarova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Fateeva
Pacific State Medical University; Khimki Clinical Hospital
1 shared publication - A.A. Plykina
Russian Society of Clinical Oncology
1 shared publication - A.S. Yakina
Center for Expertise and Quality Control of Medical Care
1 shared publication - Alexander V. Sytov
Blokhin National Medical Research Center of Oncology, Ministry of Health, Moscow, Russia
1 shared publication - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Anastasiya K. Ivanova
St. Petersburg City Clinical Oncology Dispensary
1 shared publication
Latest Publications
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Cost of supportive cancer care in the Russian Federation. Part 1
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.